实用临床医药杂志2011，Vol.15Issue(15)：43-45,3.
FOLFOX4与XELOX方案治疗晚期结直肠癌的临床观察
The clinical effect of FOLFOX4 and XELOX in advanced colorectal cancer patients
胡薛莉 1张航 1汪舸 1钱科卿1
作者信息
- 1. 南京医科大学附属常州第二人民医院肿瘤科,江苏常州,213003
- 折叠
摘要
Abstract
Objective To evaluate the clinical efficacy and toxicity of FOLFOX4 versus XELOX in the treatment of advanced colorectal cancer. Methods Fifty - six cases with advanced colorectal cancer were enrolled into this study. They were randomly but equally divided into FOL FOX4 group and XELOX group respectively. All patients received more than four cycles of chemotherapy. The efficacy and toxicity were evaluated according to WHO standard. Results Fifty - four cases were available for objective response, 2 cases were abandoned for not tolerating toxicity in FOLFOX4 group. The overall response rate was 46.2% (CR3, PR9) in FOLFOX group and 42.9% (CR2, PR10) in XELOX group. The difference in response rate was not statistically significant between the two groups( P >0.05). The incidence of grade M ~ IV nausea and vomiting was significantly lower in XELOX group than in FOLFOX4 group (P<0.05), but hand and foot syndrome in XELOX group were more obvious than in FOLFOX4 group (P<0.05), and no other statistical significance existed(P>0.05). Conclusion The difference in response rate was not statistically significant between the two groups, XELOX regimen may be safer than FOLFOX4 regimen.关键词
FOLFOX4/XELOX/晚期结直肠癌Key words
FOLFOX4/XELOX/advanced colorectal cancer分类
医药卫生引用本文复制引用
胡薛莉,张航,汪舸,钱科卿..FOLFOX4与XELOX方案治疗晚期结直肠癌的临床观察[J].实用临床医药杂志,2011,15(15):43-45,3.
